Skip to main content
Signal8

COMPUGEN LTD (CGEN)

Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe. The company’s core activities center around its immuno-oncology pipeline, which includes several investigational treatments: COM701, an anti-PVRIG antibody currently undergoing Phase I clinical studies for solid tumors. COM902, a therapeutic antibody designed to target TIGIT, which is also in Phase I clinical trials as a monotherapy for advanced malignancies. Bapotulimab, an antibody targeting ILDR2, presently in Phase I clinical development for solid tumor indications. AZD2936, an innovative bispecific antibody targeting both TIGIT and PD-1, advancing through Phase I/II clinical studies for patients with advanced or metastatic non-small cell lung cancer. Additionally, Compugen maintains earlier-stage immuno-oncology programs, with a particular emphasis on myeloid targets. To further its research and development, Compugen actively fosters strategic alliances. It has a collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics that modulate immune checkpoint regulators. Another key partnership is with Bristol-Myers Squibb, aimed at evaluating the safety and tolerability of COM701 when administered alongside Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo, in patients with advanced solid tumors. The company also collaborates with Johns Hopkins School of Medicine to investigate novel T cell and myeloid checkpoint targets, and has a distinct research collaboration with Johns Hopkins University specifically dedicated to myeloid science. Furthermore, Compugen holds a licensing agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Compugen Ltd. logo

Compugen Ltd.

NASDAQ:CGENHealthcare
AH-0.51%$1.95
Close$1.96-2.97%
Mkt Cap$185.67M
EV-
Float94.61M
O/S94.73M
VOL141K sh
$ Vol$282K
RVOL0.59×
Inst Own14.8%
SI2.7%
Net Cash/Sh-
Dilution
Compugen Ltd. logoNASDAQ:CGENAH$1.95-0.51%
Short interest (FINRA)
2.7%
Oct 30 (19d)

Float 94.61M · Signal8 dilution snapshot · Aug 3, 2026

2.5M
Oct 30 (19d)prev 2.5M▲ 0.5%
9.70
Oct 30 (19d)prev 12.66▼ 23.4%
Borrow

The cost to borrow CGEN shares for a short sale and how many shares are available to borrow, refreshed through the session.

Borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
51.5%
Nov 17 (1d)prev 57.4%▼ 5.9 pts

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

158
Oct 22 (27d)prev 463▼ 65.9%
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Fails to deliver24 settlement dates
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 20262.5M sh
Oct 15, 20262.5M sh
Sep 30, 20262.4M sh
Sep 15, 20262.4M sh
Aug 31, 20262.3M sh
Latest fails to deliver
DateShares failed
Oct 22, 2026158 sh
Oct 21, 2026463 sh
Oct 2, 202612.2K sh
Oct 1, 20264.5K sh
Sep 23, 20263.5K sh

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume
Nov 17
Latest sessions
DateReported short
Nov 17, 202651.5%
Nov 16, 202657.4%
Nov 13, 202653.8%
Nov 12, 202652.1%
Nov 11, 202631.5%
90-session median 54.3%mean 52.1%range 19.1–74.2%

130 calendar days requested; 91 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.

Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for CGEN: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 2,528,041 CGEN shares were sold short (2.67% of a 94.61M-share float, 9.70 days to cover).